'We're not just all about the money' — PHARMAC defends why it still won't fund drug for rare children's disorder

One News

3 June 2021 - Under-fire PHARMAC is defending the way it funds New Zealand's drugs, with the agency's director of operations, Lisa Williams, saying it's working on better openness and transparency with Kiwis about those decisions.

However, Breakfast host John Campbell this morning called out Williams' emotive language when she called Spinraza — a treatment for spinal muscular atrophy, a rare disorder in children — "extremely expensive" but then refused to share the cost.

Read One News article

Michael Wonder

Posted by:

Michael Wonder